356069-16-4Relevant articles and documents
Synthesis of 2H- and 13C-labelled sunitinib and its primary metabolite
Elsinghorst, Paul W.,Guetschow, Michael
, p. 360 - 365 (2009)
Sunitinib (Sutent, Pfizer) was approved in 2006 for the treatment of gastrointestinal and renal cancer. Isotope-labelled derivatives have already been prepared for PET and ADME radiography. The preparation of 13C- and 2H-labelled internal standards of sunitinib (SU11248) and its primary metabolite (SU12662) for LC-MS analysis of human blood samples is presented. Copyright